Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.41 |
| ▸ | TYMP | P19971 | 2/20 | 0.38 |
| ▸ | P2RY6 | Q15077 | 3/20 | 0.34 |
| ▸ | NT5E | P21589 | 2/20 | 0.34 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.34 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.33 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.33 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.33 |
| ▸ | P2RY4 | P51582 | 2/20 | 0.33 |
| ▸ | CTSL | P07711 | 1/20 | 0.32 |
| ▸ | CTSB | P07858 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12197508 | 0.94 | POLB (0.43) | POLBABL1RIN1TYMPP2RY6 | |
| SCHEMBL14066269 | 0.91 | POLB (0.50) | POLBABL1RIN1TYMPP2RY6 | |
| SCHEMBL12197787 | 0.90 | POLB (0.40) | POLBABL1RIN1TYMPP2RY6 | |
| SCHEMBL16350596 | 0.90 | POLB (0.40) | POLBABL1RIN1TYMPP2RY6 | |
| SCHEMBL837389 | 0.90 | POLB (0.40) | POLBABL1RIN1TYMPP2RY6 | |
| SCHEMBL10095196 | 0.89 | POLB (0.39) | POLBABL1RIN1TYMPP2RY6 | |
| SCHEMBL10095143 | 0.88 | POLB (0.39) | POLBABL1RIN1TYMPP2RY6 | |
| SCHEMBL13036643 | 0.84 | TYMP (0.42) | POLBTYMPP2RY6SLC6A1SLC6A11 | |
| SCHEMBL835720 | 0.83 | POLB (0.46) | POLBABL1RIN1P2RY6NT5E | |
| SCHEMBL23157266 | 0.81 | POLB (0.56) | POLBABL1RIN1TYMPP2RY6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143396-B2 | 1-[2′, 3′ -dideoxy-3′ C- (hydroxymethyl)—beta-D-erythro-pentofuranosyl] cytosine derivatives as HIV inhibitors | MEDIVIR AB (SE) | 2012-03-27 | — | — | US | disclosed |
| EP-1899352-B1 | 1- [2' , 3' -DIDEOXY-3' C- (HYDROXYMETHYL) - BETA-D-ERYTHRO-PENTOFURANOSYL] CYTOSINE DERIVATIVES AS HIV INHIBITORS | MEDIVIR AB (SE) | 2011-10-05 | — | — | EP | disclosed |
| EP-2336135-A2 | 1-[2',3'-dideoxy-3'c-(hydroxymethyl)- beta-d-erythro-pentofuranosyl]cytosine derivatives as HIV inhibitors | Medivir AB (SE) | 2011-06-22 | — | — | EP | disclosed |
| US-20110112294-A1 | 1-[2', 3' -DIDEOXY-3' C- (HYDROXYMETHYL) - BETA-D-ERYTHRO-PENTOFURANOSYL] CYTOSINE DERIVATIVES AS HIV INHIBITORS | MEDIVIR AB (SE) | 2011-05-12 | — | — | US | disclosed |
| US-7888367-B2 | reverse transcriptase mutants which allow an obligate chain terminating nucleoside- or nucleotide phosphate to be excised from the nascent DNA strand by ATP- or pyrophosphate-mediated excision | MEDIVIR AB (SE) | 2011-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112294-A1 | 1-[2', 3' -DIDEOXY-3' C- (HYDROXYMETHYL) - BETA-D-ERYTHRO-PENTOFURANOSYL] CYTOSINE DERIVATIVES AS HIV INHIBITORS | NUDT1, RRM2, TYMP | POLB 16/4885ABL1 4053/4885RIN1 779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.